579.33

0.30% 1.75

United Therapeutics Corp (UTHR)

Overview News Price History Option Chain Financials Why UTHR Down? Discussions Forecast Stock Split

United Therapeutics Corp stock is traded at $579.33, with a volume of 124.49K. It is up +0.30% in the last 24 hours and up +8.43% over the past month. United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Previous Close:

$577.58

Open:

$575

24h Volume:

124.49K

Relative Volume:

0.26

Market Cap:

$25.38B

Revenue:

$3.18B

Net Income/Loss:

$1.33B

P/E Ratio:

20.76

EPS:

27.9001

Net Cash Flow:

$1.04B

1W Performance:

+0.80%

1M Performance:

+8.43%

6M Performance:

+33.89%

1Y Performance:

+103.14%

1-Day Range:

$573.87

$581.92

1-Week Range:

$566.12

$584.54

52-Week Range:

$272.12

$607.89

United Therapeutics Corp Stock (UTHR) Company Profile

Name

United Therapeutics Corp

Sector

Healthcare (1117)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

(301) 608-9292

Address

1000 SPRING ST, SILVER SPRING, MD

Employee

1,400

Twitter

Next Earnings Date

2026-02-25

Latest SEC Filings

UTHR's Discussions on Twitter

Compare UTHR vs TAK, ZTS, HLN, TEVA

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
UTHR United Therapeutics Corp	579.00	25.31B	3.18B	1.33B	1.04B	27.90
TAK Takeda Pharmaceutical Co Adr	17.75	56.39B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	120.26	50.78B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.605	43.02B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.41	36.81B	17.41B	1.43B	1.00B	1.2182

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Raymond James	Outperform
Oct-20-25	Initiated	Wells Fargo	Underweight
Sep-26-25	Initiated	RBC Capital Mkts	Outperform
Jun-02-25	Initiated	Cantor Fitzgerald	Overweight
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-12-24	Upgrade	Goldman	Sell → Neutral
Feb-05-24	Initiated	Leerink Partners	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Dec-06-22	Initiated	UBS	Buy
Dec-05-22	Initiated	Goldman	Sell
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Jun-25-20	Reiterated	H.C. Wainwright	Neutral
Mar-10-20	Upgrade	Jefferies	Hold → Buy
Feb-27-20	Upgrade	Cowen	Market Perform → Outperform
Jan-31-20	Upgrade	JP Morgan	Neutral → Overweight
Dec-03-19	Initiated	BofA/Merrill	Underperform
Aug-01-19	Upgrade	Jefferies	Underperform → Hold
Aug-01-19	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jul-01-19	Upgrade	Credit Suisse	Neutral → Outperform
May-17-19	Upgrade	UBS	Sell → Neutral
May-09-19	Upgrade	Credit Suisse	Underperform → Neutral
Oct-12-18	Upgrade	Standpoint Research	Hold → Buy
Aug-08-18	Downgrade	Credit Suisse	Neutral → Underperform
Apr-03-18	Upgrade	Credit Suisse	Underperform → Neutral
Feb-22-18	Reiterated	Barclays	Underweight
Jan-18-18	Resumed	Credit Suisse	Underperform
Dec-27-17	Reiterated	Wedbush	Outperform
Apr-27-17	Reiterated	Wedbush	Outperform
Mar-30-17	Initiated	UBS	Sell
Mar-16-17	Initiated	Credit Suisse	Underperform

View All

United Therapeutics Corp Stock (UTHR) Latest News

Apr 14, 2026

UNITED THERAPEUTICS CORPORATION (UTHR) - MSN

Apr 14, 2026

Rothblatt, United Therapeutics CEO, sells $5.5 million in stock - Investing.com

Apr 14, 2026

Assetmark Inc. Sells 10,952 Shares of United Therapeutics Corporation $UTHR - MarketBeat

Apr 14, 2026

Apr 13, 2026

Rothblatt, United Therapeutics CEO, sells $5.4m in UTHR stock By Investing.com - Investing.com India

Apr 13, 2026

United Therapeutics (NASDAQ:UTHR) Stock Rating Upgraded by Raymond James Financial - MarketBeat

Apr 11, 2026

Apr 10, 2026

Analyst Ratings Update: United Therapeutics (UTHR) Current Price Target Raised | UTHR Stock News - GuruFocus

Apr 10, 2026

UTHR Stock Price, Quote & Chart | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill

Apr 10, 2026

Raymond James initiates United Therapeutics stock coverage with outperform rating - Investing.com Australia

Apr 10, 2026

Rothblatt Martine a of United Therapeutics sells $5.5M in UTHR stock - Investing.com Australia

Apr 10, 2026

Apr 09, 2026

Raymond James initiates United Therapeutics stock coverage with outperform rating By Investing.com - Investing.com South Africa

Apr 09, 2026

Apr 08, 2026

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.

Apr 08, 2026

United Therapeutics’ liver device gets FDA regenerative therapy status - Investing.com

Apr 08, 2026

Bioengineered liver for acute liver failure gets key FDA designation - Stock Titan

Apr 08, 2026

Apr 07, 2026

James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat

Apr 07, 2026

Apr 06, 2026

United Therapeutics (NASDAQ:UTHR) CFO Sells $5,615,000.00 in Stock - MarketBeat

Apr 06, 2026

United Therapeutics CFO Edgemond sells $5.6m in UTHR stock By Investing.com - Investing.com Australia

Apr 06, 2026

Rothblatt (United Therapeutics) sells $5.3m in UTHR stock By Investing.com - Investing.com Canada

Apr 06, 2026

United Therapeutics CFO Edgemond sells $5.6m in UTHR stock - Investing.com

Apr 06, 2026

Rothblatt (United Therapeutics) sells $5.3m in UTHR stock - Investing.com

Apr 06, 2026

United Therapeutics rises on positive study for cornerstone drug. Why shares could run even higher - MSN

Apr 06, 2026

Perpetual Ltd Makes New Investment in United Therapeutics Corporation $UTHR - MarketBeat

Apr 06, 2026

Apr 04, 2026

United Therapeutics Corporation (UTHR) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 04, 2026

Element Squared LLC Acquires New Position in United Therapeutics Corporation $UTHR - MarketBeat

Apr 04, 2026

Apr 03, 2026

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Apr 03, 2026

Apr 02, 2026

Will United Therapeutics (UTHR) Surpass Expectations in Its Upcoming Earnings Announcement? - Bitget

Apr 02, 2026

United Therapeutics' Strong Competitive Edge and Robust Cash Flow Indicate a Sustainable Value Opportunity - Bitget

Apr 02, 2026

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,610,605.00 in Stock - MarketBeat

Apr 02, 2026